SELLAS Life Sciences (SLS) Total Liabilities (2010 - 2026)
SELLAS Life Sciences (SLS) reported Total Liabilities of $6.8 million for Q1 2026, down 6.0% year-over-year from $7.2 million in Q1 2025, and down 9.49% on a QoQ basis from $7.5 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Total Liabilities data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Total Liabilities fell 6.0% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (down 6.0% YoY) and the FY2025 annual result came in at $7.5 million, down 25.01% from the prior year.
- Total Liabilities eased to $6.8 million in Q1 2026 per SLS's latest filing, from $7.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $17.4 million in Q1 2022 and bottomed at $5.9 million in Q3 2025.
- The 5-year median for Total Liabilities is $12.2 million (2024), against an average of $11.6 million.
- The widest annual swing landed in 2022, when Total Liabilities soared 171.46%; it then plunged 51.21% in 2025.
- Tracing SLS's Total Liabilities over 5 years: stood at $16.1 million in 2022, then retreated by 11.79% to $14.2 million in 2023, then decreased by 29.79% to $10.0 million in 2024, then slipped by 25.01% to $7.5 million in 2025, then decreased by 9.49% to $6.8 million in 2026.
- Per Business Quant, the three latest SLS Total Liabilities figures stand at $6.8 million (Q1 2026), $7.5 million (Q4 2025), and $5.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 6.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.77 Mn |
| Dec 31, 2025 | 7.47 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 9.97 Mn |
| Sep 30, 2024 | 10.61 Mn |
| Jun 30, 2024 | 12.21 Mn |
| Mar 31, 2024 | 14.75 Mn |
| Dec 31, 2023 | 14.20 Mn |
| Sep 30, 2023 | 11.91 Mn |
| Jun 30, 2023 | 13.72 Mn |
| Mar 31, 2023 | 15.94 Mn |
| Dec 31, 2022 | 16.09 Mn |
| Sep 30, 2022 | 13.40 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 17.41 Mn |
| Dec 31, 2021 | 5.93 Mn |
| Sep 30, 2021 | 11.35 Mn |
| Jun 30, 2021 | 10.21 Mn |
| Mar 31, 2021 | 11.83 Mn |
| Dec 31, 2020 | 18.09 Mn |
| Sep 30, 2020 | 10.56 Mn |
| Jun 30, 2020 | 10.73 Mn |
| Mar 31, 2020 | 8.96 Mn |
| Dec 31, 2019 | 10.52 Mn |
| Sep 30, 2019 | 10.85 Mn |
| Jun 30, 2019 | 10.70 Mn |
| Mar 31, 2019 | 11.98 Mn |
| Dec 31, 2018 | 11.67 Mn |
| Sep 30, 2018 | 20.01 Mn |
| Jun 30, 2018 | 34.46 Mn |
| Mar 31, 2018 | 34.80 Mn |
| Dec 31, 2017 | 31.46 Mn |
| Sep 30, 2017 | 34.96 Mn |
| Jun 30, 2017 | 41.43 Mn |
| Mar 31, 2017 | 43.14 Mn |
| Dec 31, 2016 | 11.42 Mn |
| Sep 30, 2016 | 48.92 Mn |
| Jun 30, 2016 | 53.46 Mn |
| Mar 31, 2016 | 53.95 Mn |
| Dec 31, 2015 | 68.63 Mn |
| Sep 30, 2015 | 50.25 Mn |
| Jun 30, 2015 | 52.60 Mn |
| Mar 31, 2015 | 49.52 Mn |
| Dec 31, 2014 | 43.43 Mn |
| Sep 30, 2014 | 48.63 Mn |
| Jun 30, 2014 | 51.97 Mn |
| Mar 31, 2014 | 45.79 Mn |
| Dec 31, 2013 | 82.09 Mn |
| Sep 30, 2013 | 56.63 Mn |
| Jun 30, 2013 | 46.77 Mn |
| Mar 31, 2013 | 38.14 Mn |
| Dec 31, 2012 | 27.23 Mn |
| Sep 30, 2012 | 21.03 Mn |
| Mar 31, 2012 | 38.78 Mn |
| Dec 31, 2011 | 20.86 Mn |
| Sep 30, 2011 | 25.62 Mn |
| Jun 30, 2011 | 25.22 Mn |
| Dec 31, 2010 | 5.05 Mn |